CN112773891A - 卵形鲳鲹源无乳链球菌dna疫苗及其制备方法和应用 - Google Patents

卵形鲳鲹源无乳链球菌dna疫苗及其制备方法和应用 Download PDF

Info

Publication number
CN112773891A
CN112773891A CN202110137557.XA CN202110137557A CN112773891A CN 112773891 A CN112773891 A CN 112773891A CN 202110137557 A CN202110137557 A CN 202110137557A CN 112773891 A CN112773891 A CN 112773891A
Authority
CN
China
Prior art keywords
plasmid
streptococcus agalactiae
internalin
dna vaccine
trachinotus ovatus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110137557.XA
Other languages
English (en)
Other versions
CN112773891B (zh
Inventor
蔡小辉
彭银辉
杨绍宇
陈泓霖
龙群能
王龙文
胥鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beibu Gulf University
Original Assignee
Beibu Gulf University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beibu Gulf University filed Critical Beibu Gulf University
Priority to CN202110137557.XA priority Critical patent/CN112773891B/zh
Publication of CN112773891A publication Critical patent/CN112773891A/zh
Application granted granted Critical
Publication of CN112773891B publication Critical patent/CN112773891B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

本发明公开了一种卵形鲳鲹源无乳链球菌DNA疫苗及其制备方法和应用。所述的疫苗的核苷酸序列如SEQ ID NO:1所示,其制备方法为:根据internalin基因序列设计引物并进行PCR扩增,所得产物与pMD‑18T连接,转化DH5α后选出阳性克隆菌并扩大培养,提取质粒经验证得到pMD‑internalin重组质粒;再将该所得质粒和pcDNA3.1(+)质粒分别用限制性内切酶EcoR I和Xho I酶切,酶切产物用T4DNA连接酶连接,转化DH5α,选出阳性克隆菌提取质粒经验证即得卵形鲳鲹源无乳链球菌DNA疫苗。本发明所述疫苗免疫保护率较高,周期较长。

Description

卵形鲳鲹源无乳链球菌DNA疫苗及其制备方法和应用
技术领域
本发明涉及鱼类抵抗细菌感染的DNA疫苗,具体涉及卵形鲳鲹源无乳链球菌DNA疫苗及其制备方法和应用,属于分子生物学领域。
背景技术
卵形鲳鲹(Trachinotus ovatus),俗称金鲳,是一种暖水性中上层鱼类,基于其生长速率较快,且出口加工市场前景诱人等特点,网箱养殖规模逐年增加,已逐渐成为南方海水养殖主要品种之一。但是,因养殖规模扩张迅猛、种质下降、养殖管理水平差、近岸海区环境恶化、药物使用不当等诸多因素,卵形鲳鲹细菌病的发生越来越频繁,链球菌病害频发,给行业带来巨大损失。
无乳链球菌(Streptococcus agalactiae)是卵形鲳鲹养殖过程中普遍易发的致病菌,高发季节为水温较高的夏秋季节,主要症状有眼球突出、内鳃盖骨血管充血、游泳打转不正常、肠发炎等。对于无乳链球菌所致卵形鲳鲹疾病防治,大多采取化学消毒预防和抗生素等传统治疗方法,虽然也有一定的效果,但总体效果不佳,造成环境污染、抗药病原出现、水产品的药物残留、水体正常微生物种群失调、耐药性微生物增加、养殖动物内脏机能损伤等一系列不良后果。因此,迫切需要寻求一种安全、有效的疾病的防治手段,研发针对性的疫苗免疫产品,在养殖生产中具有重要意义。如公布号为CN107082804A的发明专利,公开一种卵形鲳鲹β-胸腺素,其中指出该卵形鲳鲹β-胸腺素能够显著抑制致病菌(爱德华氏菌、哈维氏弧菌和无乳链球菌)的生长,并且注射鱼类之后能够提高鱼类的抗病能力。
内化素(internalin)是一种定位在无乳链球菌表面,通过N端半胱氨酸连接在细菌表面的脂蛋白,是细菌侵入上皮细胞、肝细胞等非吞噬细胞并被宿主细胞内化的重要因子。目前,尚未见有以pcDNA3.1(+)为载体,构建pcDNA-internalin重组真核质粒以用于卵形鲳鲹抗无乳链球菌药物的相关报道。
发明内容
本发明要解决的技术问题是提供一种对鱼类无乳链球菌的攻毒起到良好保护效果的卵形鲳鲹源无乳链球菌DNA疫苗及其制备方法和应用。
本发明所述的卵形鲳鲹源无乳链球菌DNA疫苗,是以pcDNA3.1(+)为载体,含有无乳链球菌internalin基因片段的重组真核质粒,其核苷酸序列如SEQ ID NO:1所示。
上述卵形鲳鲹源无乳链球菌DNA疫苗的制备方法,包括以下步骤:
1)根据internalin基因的核苷酸序列设计引物,并进行PCR扩增,得到PCR产物;
2)所得PCR产物与pMD-18T载体连接,转化大肠杆菌DH5α,PCR检测筛选出阳性克隆菌;将所得阳性克隆菌扩大培养,提取质粒做双酶切及DNA测序验证,得到pMD-internalin重组质粒;
3)将pcDNA3.1(+)质粒和pMD-internalin重组质粒分别用限制性内切酶EcoR I和Xho I酶切,酶切产物用T4 DNA连接酶连接,之后转化大肠杆菌DH5α,PCR检测正确后筛选出阳性克隆菌并提取质粒做双酶切及DNA测序验证,构建得到pcDNA-internalin重组真核质粒,即为卵形鲳鲹源无乳链球菌DNA疫苗。
上述制备方法的步骤1)中,所述internalin基因的核苷酸序列如SEQ ID NO:2所示。针对internalin基因的核苷酸序列设计的引物包括正向引物和反向引物,分别如SEQID NO:3和SEQ ID NO:4所示。
本发明还提供上述卵形鲳鲹源无乳链球菌DNA疫苗在制备鱼类抗无乳链球菌药物中的应用。具体的,所述的鱼类优选为卵形鲳鲹。
与现有技术相比,本发明所述的卵形鲳鲹源无乳链球菌DNA疫苗能显著引起鱼体内相关的特异性和非特异性免疫反应,对无乳链球菌的攻毒起到良好的保护效果,注射疫苗后第3周的免疫保护率达70%以上,免疫保护率较高,周期较长,可为后期DNA疫苗在生产应用及产业化生产中提供理论基础和科学依据。
附图说明
图1为本发明实施例1中internalin基因扩增PCR产物的电泳检测图,其中M:10000蛋白marker;1:internalin扩增PCR产物。
图2为本发明实施例1中构建的pMD-internalin重组质粒菌落鉴定的电泳检测图,其中M:10000DNA marker;1:阳性菌落PCR产物;2-5:阴性菌落PCR产物。
图3为本发明实施例1中构建的pcDNA-internalin重组真核质粒的构建模拟图。
图4为本发明实施例1中构建的pcDNA-internalin重组真核质菌落鉴定的电泳检测图,其中M:10000DNA marker;1:阳性菌落PCR产物;2-5:阴性菌落PCR产物。
图5为发明实施例3中卵形鲳鲹接种pcDNA-Internalin 28d时pcDNA-internalin重组真核质粒在各组织中DNA水平和RNA水平的分布图,其中A图为DNA水平分布图,B图为RNA水平分布图,在A图和B图中,M:DL10000标记;1:鳃;2:肝脏;3:肾脏;4:头肾;5:肌肉;6:小肠。
图6为发明实施例3中不同免疫时间免疫组和对照组卵形鲳鲹血清中抗体效价比较柱状图。
具体实施方式
为了更好的解释本发明的技术方案,下面结合实施例及附图对本发明作进一步详细的描述,但本发明的实施方式不限于此。若未特别指明,实施例中所用的技术特征可以替换为具有在不背离发明构思前提下等同或相似功能或效果的其他本领域已知的技术特征。
实施例1:卵形鲳鲹源无乳链球菌DNA疫苗(以下也称为DNA疫苗pcDNA-internalin)的制备
1)internalin基因序列克隆
根据NCBI上internalin基因的核苷酸序列(GenBank登录号:MW321594,SEQ IDNO:2),设计并合成特异性引物对,其中正向引物为:InF:5’-CGGAATTCATGAAAGGTCAAAAAATTATTGCT-3’(下划线为EcoR I酶切位点,SEQ ID NO:3),反向引物为InR:5’-CCGCTCGAGTTAATGGTGATGATGACCTACATGTG-3’(下划线为Xho I酶切位点,SEQ ID NO:4)。PCR扩增的反应体系为:无乳链球菌基因组DNA模板0.5μL,引物(InF和InR)各0.5μL,10×Ex Taq Buffer 5μL,DNA聚合酶Mix 25μL,ddH2O补足至50μL。PCR扩增条件为:94℃预变性4min;94℃变性30s,58℃退火45s,72℃延伸2min,共34个循环;72℃延伸10min。PCR产物琼脂糖检测后,切胶回收,切胶回收的PCR产物电泳检测图如图1所示。
2)构建pMD-internalin重组质粒
将切胶回收的PCR产物与pMD18-T(TaKaRa公司)进行连接,按说明书操作进行。在离心管中分别加入以下体系溶液:切胶回收的PCR产物5μL,pMD18-T Vector 1μL,SolutionI 4μL,16℃水浴锅中连接过夜。
将连接产物转化至感受态DH5a中,涂布培养,挑取白色菌落,37℃摇床培养3-6h。用M13通用引物(M13F:CGCCAGGGTTTTCCCAGTCACGAC,SEQ ID NO:5;M13R:AGCGGATAACAATTTCACACAGGA,SEQ ID NO:6)和internalin基因的引物(InF/InR)同时进行菌落PCR鉴定。通过核酸电泳仪和普通凝胶成像仪对PCR产物进行检测,PCR检测筛选出阳性克隆菌。将上述所得阳性克隆菌扩大培养20mL,按照TIANGEN质粒小提中量试剂盒说明书提取质粒,进行EcoR I/Xho I双酶切和测序验证,构建得到pMD-internalin重组质粒。所得internalin基因扩增PCR产物的电泳检测图如图2所示。
3)构建pcDNA-internalin重组真核质粒
将pcDNA3.1(+)质粒(也称pcDNA空质粒或pcDNA质粒或原始质粒)和步骤2)提取的pMD-internalin重组质粒分别用限制性内切酶EcoR I和Xho I酶切,20μL体系含:EcoR I 1μL,Xho I 1μL,10×H buffer 2μL,质粒产物4μL,ddH2O 12μL。酶切产物纯化后,使用T4DNA连接酶进行连接,10μL体系如下:目的基因重组质粒酶切产物6μL,pcDNA空质粒酶切产物2μL,10×ligation buffer 1μL,T4 DNA Ligase 1μL。16℃连接过夜,连接后转化入感受态细胞DH5a中,使用pcDNA通用引物(pcDNA3.1-F:CTAGAGAACCCACTGCTTAC,SEQ ID NO:7;pcDNA3.1-R:TAGAAGGCACAGTCGAGG,SEQ ID NO:8)进行菌落鉴定(如图4所示),挑选出阳性克隆菌,使用天根生化科技(北京)有限公司的无内毒素质粒大提试剂盒提取质粒,进行EcoR I/Xho I双酶切和测序验证,构建得到pcDNA-internalin重组真核质粒(pcDNA-internalin重组真核质粒的构建模拟图如图3所示),即为卵形鲳鲹源无乳链球菌DNA疫苗(DNA疫苗pcDNA-internalin),其核苷酸序列如SEQ ID NO:1所示。
利用此发明方法,目的基因扩增后先与pMD18-T连接,对含目的基因的载体pMD18-T和pcDNA质粒载体上的酶切位点模拟建立克隆,证实酶切产物符合连接要求,然后进行酶切、连接,大大提高构建了DNA疫苗的成功率。
实施例2:DNA疫苗pcDNA-internalin免疫卵形鲳鲹
DNA疫苗制备液和原始质粒制备液(也称空载制备液):将DNA疫苗pcDNA-internalin在无菌生理盐水中稀释到终浓度100μg/mL,即为疫苗制备液。将pcDNA质粒在无菌生理盐水中稀释到终浓度100μg/mL,即为空载制备液。
将360尾健康的卵形鲳鲹(每尾体重约120g)随机分成3组,每组40尾,每组设置3个重复。分别为DNA疫苗组、空载组和对照组(生理盐水组)。采用背部肌肉注射法对大卵形鲳鲹进行免疫,DNA疫苗组:每尾鱼注射100μL浓度为100μg/mL pcDNA-internalin重组真核质粒;空载组:每尾鱼均注射100μL浓度为100μg/mL空载质粒;参照组:每尾鱼注射100μL无菌生理盐水。
实施例3:DNA疫苗pcDNA-internalin在卵形鲳鲹组织表达及其抗血清效价检测
在免疫后的第28天取卵形鲳鲹肌肉、头肾、鳃、脑、肝脏和脾脏组织,在DNA水平和RNA水平检测目的基因表达状况。以上述各组织的基因组DNA和提取RNA反转录的cDNA为模板,采用internalin的特异性引物InF和InR进行PCR扩增,扩增产物经1%琼脂糖凝胶电泳鉴定。结果显示免疫28d时,DNA和RNA水平上internalin均可在上述组织中表达(如图5所示)。
在免疫后第7d、第14d和第21d每组随机取3尾卵形鲳鲹,尾静脉采血,室温静置1h,4℃静置12h,4000r/min离心10min取上层血清,用于抗体效价的测定。血清中和抗体效价鉴定结果如图6所示,免疫组在第一周就检测到了抗体,在第三周时达到高峰,抗体效价为1:128,DNA疫苗组的血清中和抗体效价极显著高于对照组,引起了显著的抗体反应。
实施例4:DNA疫苗pcDNA-internalin对卵形鲳鲹的免疫保护率
免疫28d后,从免疫组的3组鱼中各随机取出20尾,共取出60尾实验鱼,每尾腹腔注射0.1mL 5.0×107cfu/mL的无乳链球菌活菌悬液,随机将60尾鱼平均分养在3个养殖桶内;另外从对照生理盐水组中取出60尾鱼,再随机将60尾鱼平均分养在3个养殖桶内,每尾腹腔注射0.1ml的灭菌生理盐水作为对照组。实验期间正常投喂,统计各组鱼死亡情况。第3周:实验组5尾,空载组14尾,对照组20尾;第7周:实验组10尾,空载组18尾,对照组20尾。
利用下列公式计算免疫保护率(RPS)
RPS=(1-免疫组死亡率/对照组死亡率)×照组死亡。
由此得出DNA疫苗pcDNA-internalin第3周和第7周的免疫保护率分别为75%和50%,显著高于对照组。空载组免疫保护率分别为30%和10%,揭示pcDNA-internalin重组真核质粒可能作为免疫佐剂起到一定程度的免疫增强作用。可见,本发明所述的DNA疫苗pcDNA-internalin是一种有效的DNA疫苗,其免疫保护率较高,周期较长。
序列表
<110> 北部湾大学
<120> 卵形鲳鲹源无乳链球菌DNA疫苗及其制备方法和应用
<130> 2021
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 8035
<212> DNA
<213> 人工序列()
<400> 1
gcactctcag tacaatctgc tctgatgccg catagttaag ccagtatctg ctccctgctt 60
gtgtgttgga ggtcgctgag tagtgcgcga gcaaaattta agctacaaca aggcaaggct 120
tgaccgacaa ttgcatgaag aatctgctta gggttaggcg ttttgcgctg cttcgcgatg 180
tacgggccag atatacgcgt tgacattgat tattgactag ttattaatag taatcaatta 240
cggggtcatt agttcatagc ccatatatgg agttccgcgt tacataactt acggtaaatg 300
gcccgcctgg ctgaccgccc aacgaccccc gcccattgac gtcaataatg acgtatgttc 360
ccatagtaac gccaataggg actttccatt gacgtcaatg ggtggagtat ttacggtaaa 420
ctgcccactt ggcagtacat caagtgtatc atatgccaag tacgccccct attgacgtca 480
atgacggtaa atggcccgcc tggcattatg cccagtacat gaccttatgg gactttccta 540
cttggcagta catctacgta ttagtcatcg ctattaccat ggtgatgcgg ttttggcagt 600
acatcaatgg gcgtggatag cggtttgact cacggggatt tccaagtctc caccccattg 660
acgtcaatgg gagtttgttt tggcaccaaa atcaacggga ctttccaaaa tgtcgtaaca 720
actccgcccc attgacgcaa atgggcggta ggcgtgtacg gtgggaggtc tatataagca 780
gagctctctg gctaactaga gaacccactg cttactggct tatcgaaatt aatacgactc 840
actataggga gacccaagct ggctagcgtt taaacttaag cttggtaccg agctcggatc 900
cactagtcca gtgtggtgga attcatgaaa ggtcaaaaaa ttattgctct agctggtctt 960
gtcctgtcat gccattttgc tcttacggca tgtcatactc aagaacacaa aaattcttat 1020
catattaaaa caaagcaggt tgctaagaaa aaagctaata aaaagaaagt ctctgttaag 1080
gaaagtcata aaaaacgcaa gggtgttgca ggggttgact ttccaactga tgatggcttt 1140
ttactgacta aagattcgaa gattttatct catacagatt ctggaatcgt tgtagcacat 1200
ggaaatcatt ctcattttat tttttactct gatttaaaag gttcaaaatt tagctattta 1260
atccctaatg ctaatgcaaa aactaataaa aatcaagcgg taagaaactt taaagcaggg 1320
gcggtagctg ttaatacatt aaatgatggc tatgttttta atcccgcaga tattgtttca 1380
gaagatgcta atggctacgt ggtcagacat ggtgaccatt tccactatat tccaaaagca 1440
agtttatctc agcaaaagca agtacaagca agtagagctg tttcacgttt aggaaatcaa 1500
agtaatagcc attacagggt taatagttct aaaattgcag ggcttcacta cccaacaagt 1560
gatggtttct tatttaatgg acgaggaata aaaggcacta ccccaacagg tattttagta 1620
gaacatcata atcatctgca ttttattagt tttgctgatt taagaaaagg ggggtgggga 1680
tcaattgctg accgttacca accacaaaag aaagctgatt ctaaaaaaca gtcaccatca 1740
agtaaaaagc caagaaatga aaatacttta cctaaggaca tcaaagataa gctagcttac 1800
cttgctcgtg aattacattt agatatttca cgtatcagag tccttaaaac actaaatggt 1860
gaaattggat ttgaataccc acatgatgat catacacatg ttattatggc caaagatatt 1920
gatctaagta agccaattcc aaatccacat catgatgacg aagatcatca caaaggtcat 1980
caccatgatg agtccgacca taagcatgaa gaacacgagc acactaaatc aaataaatta 2040
tctgatgaaa atcaaaagaa attaatttat ttagcagaga agcttggttt aaatcctaat 2100
caaattgaag tattaacgtc agaggatgga agtatcatct ttaagtatcc acatgatgac 2160
cactcacaca ctatagcaag taaggatatc gaaattggga agcctatccc agatggacac 2220
cacgatcact ctcatgcaaa agataaagtt ggtatggcaa ctctaaaaca aattggtttt 2280
gatgatgaga ttattcagga tattctgcat gcagatgctc caacaccatt cccatcaaat 2340
gaaactaatc ctgaaaaaat gcgtcagtgg cttgcaactg ttactaagat taacattgga 2400
caaagaacca atccattcca gcgttttggt ctatcattga tgcctaatat tgaagttcta 2460
ggaattgggt ttactccgat taatgatatg acgccagttt tgcaattcaa aaaacttaaa 2520
cagctttgga tgacaaatac tggtattaca gattattctt tccttgataa gatgccacta 2580
ttagaaggat tggatatttc acaaaacggt attaaggatt tatctttcct tacaaaatat 2640
aaacaattaa gtcttattgc tgcagctaat aatggcatta cttcgctaaa accattggct 2700
gaattaccaa accttcaatt cttagttttg agtcataaca atatctctga cttgacaccg 2760
ttatcaaact tgacaaaact ccaagaattg caccttgatc ataataatgt gaagaattta 2820
agtgcacttt ctggtaaaaa agatttgaaa gttctagatt tatcaaacaa taaatccgca 2880
gacttatcga ctctaaaaac aactagtctt gagacgcttc ttttaaatga gacgaataca 2940
agcaatctaa gtttcttaaa gcaaaatcct aaggtatcta atttaacaat taataatgcg 3000
aaattatcat cattagatgg tattgaagag agcgatgaaa ttgttaaagt agaagctgaa 3060
gggaaccaaa ttaagtcact agtattgaaa aataaacaag gttcgttaaa attcttgaat 3120
gtgactaata atcagttaac atcacttgaa ggtgttaata attatacttc acttgagacc 3180
ttaagtgttt ctagaaataa acttaaatct ttagatatta aaacacctaa caaaacagtt 3240
acaaatcttg attttagcca taacaatgtt ccaacatcac aattgaaatt gaatgaaaaa 3300
aatattcctg aagcagtagc taagaatttt ccagcagttg tagaaggttc aatggttgga 3360
aatggtagtc ttgctgaaaa agcagctatg gcttctaaag aggacaaaca agtttcagat 3420
aatactaatc accaaaaaaa cactgaaaaa tctgctcaag cgaatgctga tagtaaaaaa 3480
gaaaacccta aaacacatga tgaacatcat gaccatgaag aaacagatca tgcacatgta 3540
ggtcatcatc accatccgct cgagtctaga gggcccgttt aaacccgctg atcagcctcg 3600
actgtgcctt ctagttgcca gccatctgtt gtttgcccct cccccgtgcc ttccttgacc 3660
ctggaaggtg ccactcccac tgtcctttcc taataaaatg aggaaattgc atcgcattgt 3720
ctgagtaggt gtcattctat tctggggggt ggggtggggc aggacagcaa gggggaggat 3780
tgggaagaca atagcaggca tgctggggat gcggtgggct ctatggcttc tgaggcggaa 3840
agaaccagct ggggctctag ggggtatccc cacgcgccct gtagcggcgc attaagcgcg 3900
gcgggtgtgg tggttacgcg cagcgtgacc gctacacttg ccagcgccct agcgcccgct 3960
cctttcgctt tcttcccttc ctttctcgcc acgttcgccg gctttccccg tcaagctcta 4020
aatcgggggc tccctttagg gttccgattt agtgctttac ggcacctcga ccccaaaaaa 4080
cttgattagg gtgatggttc acgtagtggg ccatcgccct gatagacggt ttttcgccct 4140
ttgacgttgg agtccacgtt ctttaatagt ggactcttgt tccaaactgg aacaacactc 4200
aaccctatct cggtctattc ttttgattta taagggattt tgccgatttc ggcctattgg 4260
ttaaaaaatg agctgattta acaaaaattt aacgcgaatt aattctgtgg aatgtgtgtc 4320
agttagggtg tggaaagtcc ccaggctccc cagcaggcag aagtatgcaa agcatgcatc 4380
tcaattagtc agcaaccagg tgtggaaagt ccccaggctc cccagcaggc agaagtatgc 4440
aaagcatgca tctcaattag tcagcaacca tagtcccgcc cctaactccg cccatcccgc 4500
ccctaactcc gcccagttcc gcccattctc cgccccatgg ctgactaatt ttttttattt 4560
atgcagaggc cgaggccgcc tctgcctctg agctattcca gaagtagtga ggaggctttt 4620
ttggaggcct aggcttttgc aaaaagctcc cgggagcttg tatatccatt ttcggatctg 4680
atcaagagac aggatgagga tcgtttcgca tgattgaaca agatggattg cacgcaggtt 4740
ctccggccgc ttgggtggag aggctattcg gctatgactg ggcacaacag acaatcggct 4800
gctctgatgc cgccgtgttc cggctgtcag cgcaggggcg cccggttctt tttgtcaaga 4860
ccgacctgtc cggtgccctg aatgaactgc aggacgaggc agcgcggcta tcgtggctgg 4920
ccacgacggg cgttccttgc gcagctgtgc tcgacgttgt cactgaagcg ggaagggact 4980
ggctgctatt gggcgaagtg ccggggcagg atctcctgtc atctcacctt gctcctgccg 5040
agaaagtatc catcatggct gatgcaatgc ggcggctgca tacgcttgat ccggctacct 5100
gcccattcga ccaccaagcg aaacatcgca tcgagcgagc acgtactcgg atggaagccg 5160
gtcttgtcga tcaggatgat ctggacgaag agcatcaggg gctcgcgcca gccgaactgt 5220
tcgccaggct caaggcgcgc atgcccgacg gcgaggatct cgtcgtgacc catggcgatg 5280
cctgcttgcc gaatatcatg gtggaaaatg gccgcttttc tggattcatc gactgtggcc 5340
ggctgggtgt ggcggaccgc tatcaggaca tagcgttggc tacccgtgat attgctgaag 5400
agcttggcgg cgaatgggct gaccgcttcc tcgtgcttta cggtatcgcc gctcccgatt 5460
cgcagcgcat cgccttctat cgccttcttg acgagttctt ctgagcggga ctctggggtt 5520
cgaaatgacc gaccaagcga cgcccaacct gccatcacga gatttcgatt ccaccgccgc 5580
cttctatgaa aggttgggct tcggaatcgt tttccgggac gccggctgga tgatcctcca 5640
gcgcggggat ctcatgctgg agttcttcgc ccaccccaac ttgtttattg cagcttataa 5700
tggttacaaa taaagcaata gcatcacaaa tttcacaaat aaagcatttt tttcactgca 5760
ttctagttgt ggtttgtcca aactcatcaa tgtatcttat catgtctgta taccgtcgac 5820
ctctagctag agcttggcgt aatcatggtc atagctgttt cctgtgtgaa attgttatcc 5880
gctcacaatt ccacacaaca tacgagccgg aagcataaag tgtaaagcct ggggtgccta 5940
atgagtgagc taactcacat taattgcgtt gcgctcactg cccgctttcc agtcgggaaa 6000
cctgtcgtgc cagctgcatt aatgaatcgg ccaacgcgcg gggagaggcg gtttgcgtat 6060
tgggcgctct tccgcttcct cgctcactga ctcgctgcgc tcggtcgttc ggctgcggcg 6120
agcggtatca gctcactcaa aggcggtaat acggttatcc acagaatcag gggataacgc 6180
aggaaagaac atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa aggccgcgtt 6240
gctggcgttt ttccataggc tccgcccccc tgacgagcat cacaaaaatc gacgctcaag 6300
tcagaggtgg cgaaacccga caggactata aagataccag gcgtttcccc ctggaagctc 6360
cctcgtgcgc tctcctgttc cgaccctgcc gcttaccgga tacctgtccg cctttctccc 6420
ttcgggaagc gtggcgcttt ctcatagctc acgctgtagg tatctcagtt cggtgtaggt 6480
cgttcgctcc aagctgggct gtgtgcacga accccccgtt cagcccgacc gctgcgcctt 6540
atccggtaac tatcgtcttg agtccaaccc ggtaagacac gacttatcgc cactggcagc 6600
agccactggt aacaggatta gcagagcgag gtatgtaggc ggtgctacag agttcttgaa 6660
gtggtggcct aactacggct acactagaag aacagtattt ggtatctgcg ctctgctgaa 6720
gccagttacc ttcggaaaaa gagttggtag ctcttgatcc ggcaaacaaa ccaccgctgg 6780
tagcggtttt tttgtttgca agcagcagat tacgcgcaga aaaaaaggat ctcaagaaga 6840
tcctttgatc ttttctacgg ggtctgacgc tcagtggaac gaaaactcac gttaagggat 6900
tttggtcatg agattatcaa aaaggatctt cacctagatc cttttaaatt aaaaatgaag 6960
ttttaaatca atctaaagta tatatgagta aacttggtct gacagttacc aatgcttaat 7020
cagtgaggca cctatctcag cgatctgtct atttcgttca tccatagttg cctgactccc 7080
cgtcgtgtag ataactacga tacgggaggg cttaccatct ggccccagtg ctgcaatgat 7140
accgcgagac ccacgctcac cggctccaga tttatcagca ataaaccagc cagccggaag 7200
ggccgagcgc agaagtggtc ctgcaacttt atccgcctcc atccagtcta ttaattgttg 7260
ccgggaagct agagtaagta gttcgccagt taatagtttg cgcaacgttg ttgccattgc 7320
tacaggcatc gtggtgtcac gctcgtcgtt tggtatggct tcattcagct ccggttccca 7380
acgatcaagg cgagttacat gatcccccat gttgtgcaaa aaagcggtta gctccttcgg 7440
tcctccgatc gttgtcagaa gtaagttggc cgcagtgtta tcactcatgg ttatggcagc 7500
actgcataat tctcttactg tcatgccatc cgtaagatgc ttttctgtga ctggtgagta 7560
ctcaaccaag tcattctgag aatagtgtat gcggcgaccg agttgctctt gcccggcgtc 7620
aatacgggat aataccgcgc cacatagcag aactttaaaa gtgctcatca ttggaaaacg 7680
ttcttcgggg cgaaaactct caaggatctt accgctgttg agatccagtt cgatgtaacc 7740
cactcgtgca cccaactgat cttcagcatc ttttactttc accagcgttt ctgggtgagc 7800
aaaaacagga aggcaaaatg ccgcaaaaaa gggaataagg gcgacacgga aatgttgaat 7860
actcatactc ttcctttttc aatattattg aagcatttat cagggttatt gtctcatgag 7920
cggatacata tttgaatgta tttagaaaaa taaacaaata ggggttccgc gcacatttcc 7980
ccgaaaagtg ccacctgacg tcgacggatc gggagatctc ccgatcccct atggt 8035
<210> 2
<211> 2634
<212> DNA
<213> 人工序列()
<400> 2
atgaaaggtc aaaaaattat tgctctagct ggtcttgtcc tgtcatgcca ttttgctctt 60
acggcatgtc atactcaaga acacaaaaat tcttatcata ttaaaacaaa gcaggttgct 120
aagaaaaaag ctaataaaaa gaaagtctct gttaaggaaa gtcataaaaa acgcaagggt 180
gttgcagggg ttgactttcc aactgatgat ggctttttac tgactaaaga ttcgaagatt 240
ttatctcata cagattctgg aatcgttgta gcacatggaa atcattctca ttttattttt 300
tactctgatt taaaaggttc aaaatttagc tatttaatcc ctaatgctaa tgcaaaaact 360
aataaaaatc aagcggtaag aaactttaaa gcaggggcgg tagctgttaa tacattaaat 420
gatggctatg tttttaatcc cgcagatatt gtttcagaag atgctaatgg ctacgtggtc 480
agacatggtg accatttcca ctatattcca aaagcaagtt tatctcagca aaagcaagta 540
caagcaagta gagctgtttc acgtttagga aatcaaagta atagccatta cagggttaat 600
agttctaaaa ttgcagggct tcactaccca acaagtgatg gtttcttatt taatggacga 660
ggaataaaag gcactacccc aacaggtatt ttagtagaac atcataatca tctgcatttt 720
attagttttg ctgatttaag aaaagggggg tggggatcaa ttgctgaccg ttaccaacca 780
caaaagaaag ctgattctaa aaaacagtca ccatcaagta aaaagccaag aaatgaaaat 840
actttaccta aggacatcaa agataagcta gcttaccttg ctcgtgaatt acatttagat 900
atttcacgta tcagagtcct taaaacacta aatggtgaaa ttggatttga atacccacat 960
gatgatcata cacatgttat tatggccaaa gatattgatc taagtaagcc aattccaaat 1020
ccacatcatg atgacgaaga tcatcacaaa ggtcatcacc atgatgagtc cgaccataag 1080
catgaagaac acgagcacac taaatcaaat aaattatctg atgaaaatca aaagaaatta 1140
atttatttag cagagaagct tggtttaaat cctaatcaaa ttgaagtatt aacgtcagag 1200
gatggaagta tcatctttaa gtatccacat gatgaccact cacacactat agcaagtaag 1260
gatatcgaaa ttgggaagcc tatcccagat ggacaccacg atcactctca tgcaaaagat 1320
aaagttggta tggcaactct aaaacaaatt ggttttgatg atgagattat tcaggatatt 1380
ctgcatgcag atgctccaac accattccca tcaaatgaaa ctaatcctga aaaaatgcgt 1440
cagtggcttg caactgttac taagattaac attggacaaa gaaccaatcc attccagcgt 1500
tttggtctat cattgatgcc taatattgaa gttctaggaa ttgggtttac tccgattaat 1560
gatatgacgc cagttttgca attcaaaaaa cttaaacagc tttggatgac aaatactggt 1620
attacagatt attctttcct tgataagatg ccactattag aaggattgga tatttcacaa 1680
aacggtatta aggatttatc tttccttaca aaatataaac aattaagtct tattgctgca 1740
gctaataatg gcattacttc gctaaaacca ttggctgaat taccaaacct tcaattctta 1800
gttttgagtc ataacaatat ctctgacttg acaccgttat caaacttgac aaaactccaa 1860
gaattgcacc ttgatcataa taatgtgaag aatttaagtg cactttctgg taaaaaagat 1920
ttgaaagttc tagatttatc aaacaataaa tccgcagact tatcgactct aaaaacaact 1980
agtcttgaga cgcttctttt aaatgagacg aatacaagca atctaagttt cttaaagcaa 2040
aatcctaagg tatctaattt aacaattaat aatgcgaaat tatcatcatt agatggtatt 2100
gaagagagcg atgaaattgt taaagtagaa gctgaaggga accaaattaa gtcactagta 2160
ttgaaaaata aacaaggttc gttaaaattc ttgaatgtga ctaataatca gttaacatca 2220
cttgaaggtg ttaataatta tacttcactt gagaccttaa gtgtttctag aaataaactt 2280
aaatctttag atattaaaac acctaacaaa acagttacaa atcttgattt tagccataac 2340
aatgttccaa catcacaatt gaaattgaat gaaaaaaata ttcctgaagc agtagctaag 2400
aattttccag cagttgtaga aggttcaatg gttggaaatg gtagtcttgc tgaaaaagca 2460
gctatggctt ctaaagagga caaacaagtt tcagataata ctaatcacca aaaaaacact 2520
gaaaaatctg ctcaagcgaa tgctgatagt aaaaaagaaa accctaaaac acatgatgaa 2580
catcatgacc atgaagaaac agatcatgca catgtaggtc atcatcacca ttaa 2634
<210> 3
<211> 32
<212> DNA
<213> 人工序列()
<400> 3
cggaattcat gaaaggtcaa aaaattattg ct 32
<210> 4
<211> 35
<212> DNA
<213> 人工序列()
<400> 4
ccgctcgagt taatggtgat gatgacctac atgtg 35
<210> 5
<211> 24
<212> DNA
<213> 人工序列()
<400> 5
cgccagggtt ttcccagtca cgac 24
<210> 6
<211> 24
<212> DNA
<213> 人工序列()
<400> 6
agcggataac aatttcacac agga 24
<210> 7
<211> 20
<212> DNA
<213> 人工序列()
<400> 7
ctagagaacc cactgcttac 20
<210> 8
<211> 18
<212> DNA
<213> 人工序列()
<400> 8
tagaaggcac agtcgagg 18

Claims (6)

1.一种卵形鲳鲹源无乳链球菌DNA疫苗,其特征是,该疫苗为以pcDNA3.1(+)为载体,含有无乳链球菌internalin基因片段的重组真核质粒,其核苷酸序列如SEQ ID NO:1所示。
2.权利要求1所述卵形鲳鲹源无乳链球菌DNA疫苗的制备方法,包括以下步骤:
1)根据internalin基因的核苷酸序列设计引物,并进行PCR扩增,得到PCR产物;
2)所得PCR产物与pMD-18T载体连接,转化大肠杆菌DH5α,PCR检测筛选出阳性克隆菌;将所得阳性克隆菌扩大培养,提取质粒做双酶切及DNA测序验证,得到pMD-internalin重组质粒;
3)将pcDNA3.1(+)质粒和pMD-internalin重组质粒分别用限制性内切酶EcoR I和XhoI酶切,酶切产物用T4 DNA连接酶连接,之后转化大肠杆菌DH5α,PCR检测筛选出阳性克隆菌并提取质粒做双酶切及DNA测序验证,构建得到pcDNA-internalin重组真核质粒,即为卵形鲳鲹源无乳链球菌DNA疫苗。
3.根据权利要求2所述的制备方法,其特征是,步骤1)中,所述internalin基因的核苷酸序列如SEQ ID NO:2所示。
4.根据权利要求2或3所述的制备方法,其特征是,步骤1)中,根据internalin基因的核苷酸序列设计的引物分别如SEQ ID NO:3和SEQ ID NO:4所示。
5.权利要求1所述卵形鲳鲹源无乳链球菌DNA疫苗在制备鱼类抗无乳链球菌药物中的应用。
6.根据权利要求5所述的应用,其特征是,所述的鱼类为卵形鲳鲹。
CN202110137557.XA 2021-02-01 2021-02-01 卵形鲳鲹源无乳链球菌dna疫苗及其制备方法和应用 Active CN112773891B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110137557.XA CN112773891B (zh) 2021-02-01 2021-02-01 卵形鲳鲹源无乳链球菌dna疫苗及其制备方法和应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110137557.XA CN112773891B (zh) 2021-02-01 2021-02-01 卵形鲳鲹源无乳链球菌dna疫苗及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN112773891A true CN112773891A (zh) 2021-05-11
CN112773891B CN112773891B (zh) 2022-03-25

Family

ID=75760283

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110137557.XA Active CN112773891B (zh) 2021-02-01 2021-02-01 卵形鲳鲹源无乳链球菌dna疫苗及其制备方法和应用

Country Status (1)

Country Link
CN (1) CN112773891B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115287244A (zh) * 2022-06-28 2022-11-04 北部湾大学 鱼源无乳链球菌internalin基因LRR结构域敲除突变株及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297183A1 (en) * 2007-08-06 2010-11-25 Elizabert Hilda Smith Immunogenic streptococcus proteins
CN104623649A (zh) * 2015-02-28 2015-05-20 通威股份有限公司 一种预防金鲳鱼无乳链球菌病的疫苗
CN107502622A (zh) * 2016-06-14 2017-12-22 广东省农业科学院动物卫生研究所 Sip基因重组载体、壳聚糖‑PLGA包裹Sip基因DNA疫苗及其制备方法和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297183A1 (en) * 2007-08-06 2010-11-25 Elizabert Hilda Smith Immunogenic streptococcus proteins
CN104623649A (zh) * 2015-02-28 2015-05-20 通威股份有限公司 一种预防金鲳鱼无乳链球菌病的疫苗
CN107502622A (zh) * 2016-06-14 2017-12-22 广东省农业科学院动物卫生研究所 Sip基因重组载体、壳聚糖‑PLGA包裹Sip基因DNA疫苗及其制备方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DQ242614.1: "Streptococcus agalactiae Blr (blr) gene, complete cds", 《GENBANK》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115287244A (zh) * 2022-06-28 2022-11-04 北部湾大学 鱼源无乳链球菌internalin基因LRR结构域敲除突变株及其制备方法和应用

Also Published As

Publication number Publication date
CN112773891B (zh) 2022-03-25

Similar Documents

Publication Publication Date Title
US20230293728A1 (en) Liver-Specific Nucleic Acid Regulatory Elements and Methods and Use Thereof
CN112773891B (zh) 卵形鲳鲹源无乳链球菌dna疫苗及其制备方法和应用
CN1067722C (zh) 腺病毒载体
CN104059942B (zh) 新城疫病毒耐热活疫苗载体系统及其应用
US7939056B2 (en) Interleukin-10 compositions for the treatment of adenocarcinomas
AU2019275585B2 (en) PRRSV minor protein-containing recombinant viral vectors and methods of making and use thereof
CN114026115A (zh) 用于溶酶体病症的基因疗法
CN111057715B (zh) 基于双启动子拯救猪塞尼卡病毒反向遗传操作系统及其建立方法
AU2003281310B2 (en) Tumor-lysing virus growing selectively in tumor cells
JP7074864B2 (ja) 組換えワクシニアウイルスおよびそれを含む医薬組成物
CN108624563A (zh) 能高效分泌bFGF的人脐带间充质干细胞的制备方法及其应用
US8058248B2 (en) Foot and mouth disease virus vaccine comprising interferons
CN110714027A (zh) 一种表达质粒、用于包装二代腺病毒的细胞株及其应用
KR20020001846A (ko) 폐순환승압을 치료하기 위한 맥관형성 인자를 암호화 하는핵산을 포함하는 재조합 결손 아데노바이러스의 용도
CN112680462B (zh) 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用
KR20050035511A (ko) 폴리펩타이드들을 포함하는 글리코실포스파티딜이노시톨
KR20210141997A (ko) 세포의 유전적 변형을 위한 발현 작제물
JPH09510357A (ja) 酸性繊維芽細胞成長因子(aFGF)をコードする組み換えアデノウィルス
WO2023099927A1 (en) Method for the preparation of a recombinant type ii transmembrane protease serine fragment, said fragment, and its use
US20240124541A1 (en) Compositions and methods for treating obesity
WO2024025297A1 (ko) 인터루킨-21의 분비를 위한 재조합 발현 벡터 및 이로 형질전환된 약독화 살모넬라 균주
KR20230124418A (ko) 알파-1 안티 트립신 결핍증 z 타입 돌연변이의 교정을 위한 프라임에디팅 가이드 rna를 포함하는 프라임에딩팅용 조성물
MXPA99003528A (en) Uses of keratinocyte growth factor-2
PL229055B1 (pl) Sposób otrzymywania rekombinantowego szczepu Escherichia coli Rosetta (DE3) pLysS oraz sposób wytwarzania białka syntazy trehalozy Deinococcus radiodurans DSMZ 20539

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant